Beta thalassemia. Beta thalassemia
Conditions
Interventions
Intervention 1: Intervention group: Patients are randomly divided into two groups: A, who recieves n-acetylcysteine orally at a dose of 10 mg per body weight (one 600 mg tablet per day) for one month.
Sponsors
Mazandaran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Beta thalassemia Non-transfusion dependent Splenectomy Age above 18 years Under Aspirin therapy
Exclusion criteria
Exclusion criteria: Age less than 18 years Simultaneous consumption of other antioxidants such as vitamin C and E Diabetes Irregular use of N-acetylcysteine
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reduction of at least 50% in anticoagulation panel. Timepoint: At the beginning of the study, one month later and the end of the second month. Method of measurement: Laboratory tests including: Factor V Leiden; c and s proteins; antithrombin 3; Lupus Anticoagulant. | — |
Secondary
| Measure | Time frame |
|---|---|
| Factor V Leiden. Timepoint: Upon entering the study, 1 month and 2 months later. Method of measurement: Blood test.;C and S protein. Timepoint: Upon entering the study, 1 month and 2 months later. Method of measurement: Blood test.;Antithrombin 3. Timepoint: Upon entering the study, 1 month and 2 months later. Method of measurement: Blood test.;Lupus anticoagulant. Timepoint: Upon entering the study, 1 month and 2 months later. Method of measurement: Blood test. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactHossein Karami
Mazandaran University of Medical Sciences
Outcome results
None listed